Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
UZEDY: Information from Industry
View All
Robert C. Smith, MD, PhD
JCP
Original Research
Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia
January 20, 2025
Add-on high dose sulforaphane may reduce negative symptoms in patients with schizophrenia, although the clinical significance of this reduction needs further evaluation.
Jing Huang
,
AnMei Chen
,
Hua Jin
, et al
JCP
Original Research
Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study
October 6, 2009
Jean-Pierre Lindenmayer
,
John M. Davis
,
Robert C. Smith
, et al
JCP
Article
Hyperglycemia Associated With the Use of Atypical Antipsychotics
January 9, 2001
Jean-Pierre Lindenmayer
,
Ann-Marie Nathan
,
Robert C. Smith
JCP
Original Research
Efficacy of Risperidone in Reducing Positive and Negative Symptoms in Medication-Refractory Schizophrenia: An Open Prospective Study
October 15, 1996
Robert C. Smith
,
Jayson W. Chua
,
Boris Lipetsker
, et al
